Table 21Outcomes (any bleeding) for KQ 5 over the total at-risk period

Author, YearArm, nNumber of Patients With Co-MedicationsOutcomen (%) of Patients With OutcomesRate per 100 Patient-Weeks With Co-MedicationRate per 100 Patient-Weeks Without Co-MedicationMeasures of Association, Rate Ratio* for Use vs. Non-use (95% CI)
Eriksson B.I, 2012127Rivaroxaban, 6093563Any Bleeding20 (3.6)2.04 (1.25-3.15)1.76 (1.58-1.95)1.32 (0.85-2.05)
Enoxaparin/placebo, 6107526Any Bleeding17 (3.2)2.06 (1.20-3.29)1.63 (1.46-1.81)1.40 (0.87-2.25)

CI = confidence interval

From: Results

Cover of Pharmacologic and Mechanical Prophylaxis of Venous Thromboembolism Among Special Populations
Pharmacologic and Mechanical Prophylaxis of Venous Thromboembolism Among Special Populations [Internet].
Comparative Effectiveness Reviews, No. 116.
Singh S, Haut ER, Brotman DJ, et al.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.